International Journal of Hematology

, Volume 79, Issue 3, pp 271–275 | Cite as

Durable remission by sobuzoxane in an hiv-seronegative patient with human herpesvirus 8-negative primary effusion lymphoma

  • Yoriko Inoue
  • Kunihiro Tsukasaki
  • Kazuhiro Nagai
  • Hisashi Soda
  • Masao Tomonaga
Case Report


Primary effusion lymphoma (PEL) is recognized as a unique clinicopathological entity associated with human herpesvirus 8 (HHV-8), and it occurs almost exclusively in human immunodeficiency virus (HIV)-infected individuals. In the majority of PEL cases, Epstein-Barr virus (EBV) has been found in the tumor cells as well.We describe here an elderly HIV seronegative female patient with PEL in the pleura and pericardium not associated with HHV-8 or EBV. Cytologic examinations of the pleural effusion revealed large lymphoma cells with immunophenotypes positive for CD8, CD10, CD19, CD20, CD22, CD24, CD45, and HLA-DR but negative for CD30 and surface immunoglobulin. Chromosome analysis showed complicated abnormalities including add(3)(q27). Immunoglobulin gene rearrangement was detected by Southern blotting; however, c-myc, Bcl-2, and Bcl-6 genes were not rearranged.The patient was treated with a modified CHOP (cyclophosphamide, hydroxydoxorubicin, oncovine, and prednisolone) regimen, and achieved remission. Recurrence of PEL in the pericardium as effusion lymphoma was found 3 months after the discontinuation of CHOP. After approximately 1 year of intermittent multiagent salvage therapy for pericardial recurrences, a treatment that resulted in a partial response, 3 cycles of monotherapy with sobuzoxane were administered. At the time of this report the patient had been free from PEL for more than 18 months without chemotherapy.

Key words

Primary effusion lymphoma Human herpesvirus 8 Human immunodeficiency virus Epstein-Barr virus Sobuzoxane 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Cesarman E, Chang Y, Moore PS, et al. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavitybased lymphomas. N Engl J Med. 1995;332:1186–1191.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Carbone A, Gaidano G. HHV-8-positive body-cavity-based lymphoma: a novel lymphoma entity. Br J Haematol. 1997;97:515–522.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Gaidano G, Carbone A. Primary effusion lymphoma: a liquid phase lymphoma of fluid-filled body cavities. Adv Cancer Res. 2001;80: 115–146.CrossRefPubMedGoogle Scholar
  4. 4.
    Nador RG, Cesarman E, Chadburn A, et al. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi’s sarcoma-associated herpes virus. Blood. 1996;88:645–656.Google Scholar
  5. 5.
    Carbone A, Gloghini A, Vaccher E, et al. Kaposi’s sarcoma-associated herpesvirus DNA sequences in AIDS-related and AIDS-unrelated lymphomatous effusions. Br J Haematol. 1996;94:533–543.CrossRefPubMedGoogle Scholar
  6. 6.
    Ohshima K, Ishiguro M, Yamasaki S, et al. Chromosomal and comparative genomic analyses of HHV-8-negative primary effusion lymphoma in five HIV-negative Japanese patients. Leuk Lymphoma. 2002;43:595–601.CrossRefPubMedGoogle Scholar
  7. 7.
    Saiki M, Saitoh T, Inoue M, et al. Human herpesvirus-8 negative primary effusion lymphoma with complete clinical remission after removal of ascites. Rinsho Ketsueki. 2002;43:548–553.PubMedGoogle Scholar
  8. 8.
    Hermine O, Michel M, Buzyn-Veil A, et al. Body-cavity-based lymphoma in an HIV-seronegative patient without Kaposi’s sarcomaassociated herpesvirus-like DNA sequences. N Engl J Med. 1996; 334:272–273.CrossRefPubMedGoogle Scholar
  9. 9.
    Ascoli V, Lo Coco F, Artini M, et al. Primary effusion Burkitt’s lymphoma with t(8;22) in a patient with hepatitis C virus-related cirrhosis. Hum Pathol. 1997;28:101–104.CrossRefPubMedGoogle Scholar
  10. 10.
    Ichinohasama R, Miura I, Kobayashi N, et al. Herpes virus type 8-negative primary effusion lymphoma associated with PAX-5 gene rearrangement and hepatitis C virus: a case report and review of the literature. Am J Surg Pathol. 1998;22:1528–1537.CrossRefPubMedGoogle Scholar
  11. 11.
    Tanaka S, Katano H, Tsukamoto K, et al. HHV8-negative primary effusion lymphoma of the peritoneal cavity presenting with a distinct immunohistochemical phenotype. Pathol Int. 2001;51:293–300.CrossRefPubMedGoogle Scholar
  12. 12.
    Ashihara E, Shimazaki C, Hirai H, et al. Human herpes virus 8-negative primary effusion lymphoma in a patient with a ventriculoperitoneal shunt tube. Int J Hematol. 2001;74:327–332.CrossRefPubMedGoogle Scholar
  13. 13.
    Yamamoto Y, Kitajima H, Sakihana H, et al. CD3+CD4-CD8- TCR-alphabeta+ T-cell lymphoma with clinical features of primary effusion lymphoma: an autopsy case. Int J Hematol. 2001;74: 442–446.CrossRefPubMedGoogle Scholar
  14. 14.
    Carbone A, Cilia AM, Gloghini A, et al. Establishment of HHV-8- positive and HHV-8-negative lymphoma cell lines from primary lymphomatous effusions. Int J Cancer. 1997;73:562–569.CrossRefPubMedGoogle Scholar
  15. 15.
    Rodriguez J, Romaguera JE, Katz RL, et al. Primary effusion lymphoma in an HIV-negative patient with no serologic evidence of Kaposi’s sarcoma virus. Leuk Lymphoma. 2001;41:185–189.CrossRefPubMedGoogle Scholar
  16. 16.
    Hara T, Nishi S, Horimoto A, et al. Primary effusion lymphoma in a patient with hepatitis C virus-related liver cirrhosis. J Gastroenterol Hepatol. 2001;16:948–949.CrossRefPubMedGoogle Scholar
  17. 17.
    Katano H, Hoshino Y, Morishita Y, et al. Establishing and characterizing a CD30-positive cell line harboring HHV-8 from a primary effusion lymphoma. J Med Virol. 1999;58:394–401.CrossRefPubMedGoogle Scholar
  18. 18.
    Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesviruslike DNA sequences in AIDS-associated Kaposi’s sarcoma. Science. 1994;266:1865–1869.CrossRefPubMedGoogle Scholar
  19. 19.
    Loughran TP Jr, Zambello R, Ashley R, et al. Failure to detect Epstein-Barr virus DNA in peripheral blood mononuclear cells of most patients with large granular lymphocyte leukemia. Blood. 1993;81:2723–2727.PubMedGoogle Scholar
  20. 20.
    Joh T, Yamada Y, Seto M, et al. Expression of CD8beta and alteration of cell surface phenotype in adult T-cell leukaemia cells. Br J Haematol. 1997;98:151–156.CrossRefPubMedGoogle Scholar
  21. 21.
    Yoshida M, Maehara Y, Sugimachi K. MST-16, a novel bisdioxopiperazine anticancer agent, ameliorates doxorubicin-induced acute toxicity while maintaining antitumor efficacy. Clin Cancer Res. 1999;5:4295–300.PubMedGoogle Scholar
  22. 22.
    Kagami Y, Ariyoshi Y, Horiuchi A, et al. Feasibility of salvage chemotherapy for refractory or relapsed non-Hodgkin’s lymphoma with two topoisomerase II inhibitors, MST-16 and VP-16. MST-16 Study Group. Int J Hematol. 1996;64:221–229.CrossRefPubMedGoogle Scholar
  23. 23.
    Ohno R, Yamada K, Hirano M, et al. Phase II study: treatment of non-Hodgkin’s lymphoma with an oral antitumor derivative of bis(2, 6-dioxopiperazine). J Natl Cancer Inst. 1992;84:435–438.CrossRefPubMedGoogle Scholar
  24. 24.
    Perez CL, Rudoy S. Anti-CD20 monoclonal antibody treatment of human herpesvirus 8-associated, body cavity-based lymphoma with an unusual phenotype in a human immunodeficiency virusnegative patient. Clin Diagn Lab Immunol. 2001;8:993–996.PubMedPubMedCentralGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2004

Authors and Affiliations

  • Yoriko Inoue
    • 1
  • Kunihiro Tsukasaki
    • 1
  • Kazuhiro Nagai
    • 2
  • Hisashi Soda
    • 3
  • Masao Tomonaga
    • 1
  1. 1.Department of Hematology, Molecular Medicine Unit, Atomic Bomb Disease InstituteNagasaki University Graduate School of Biomedical SciencesNagasakiJapan
  2. 2.Transfusion ServiceNagasaki University HospitalNagasakiJapan
  3. 3.Department of Internal MedicineIsahaya Insurance General HospitalNagasakiJapan

Personalised recommendations